Basiliximab (Anti-IL-2R alpha / CD25) Biosimilar In Vivo Antibody (Fc Reduced)

(No reviews yet) Write a Review
SKU:
IVMB0231
Product Type:
Biosimilar In Vivo Antibody
Antibody Type:
Monoclonal Antibody
Protein:
CD25
Clone:
Hu107
Isotype:
IgG1 kappa
Reactivity:
Human
Reactivity:
NHP - Rhesus Monkey
Reactivity:
NHP - Cynomolgus Monkey
Synonyms:
IL-2-RA, IL2-RA, TAC antigen, p55, CD25

Description

system_update_altDatasheet
Product Name:Basiliximab (Anti-IL-2R alpha / CD25) Biosimilar In Vivo Antibody (Fc Reduced)
Product Code:IVMB0231
Clone:Hu107
Protein:CD25
Product Type:Biosimilar Recombinant Human Monoclonal Antibody
Synonyms:IL-2-RA, IL2-RA, TAC antigen, p55, CD25
Isotype:Human IgG1κ
Reactivity:Human/Rhesus Monkey/Cynomolgus Monkey
Immunogen:Human CD25
Applications:B, CyTOF®, FC, IF, IHC, WB
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:>95% by SDS-PAGE and HPLC
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:B, CyTOF®, FC, IF, IHC, WB
Recommended Usage:FC
The suggested concentration for Basiliximab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 µg per 106 in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.
Reactivity:Human/Rhesus Monkey/Cynomolgus Monkey
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only.
Antigen Distribution:IL-2Rα is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes.
Immunogen:Human CD25
Concentration:≥ 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:>95% by SDS-PAGE and HPLC
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.
Protein:CD25
View AllClose

0 Reviews

View AllClose

Related Products